Close 2026-08-21 1267 scanned A

SPARC

Sun Pharma Advanced Research Company Limited
HealthcareMid capRs 6,383 crRs 16.8 cr traded a day
Close on 2026-08-21
196.71
−1.44%
52-week range52% of the way up
108.71277.57
Market cap
6,383 cr
P/E (TTM)
4.0×
industry 44×
EPS (TTM)
48.71
Revenue YoY
+137.5%
Q1 FY27
Net margin
-52.1%
+518.4pt vs a year ago
Growth trend
-10953.5pt
vs last quarter’s YoY
1 month
-8.3%
Below 52w high
41.1%
RSI (14)
39
Daily swing
3.7%
average true range
Volume
0.3×
vs 20-day average
Traded
Rs 17 cr
median day
Close200-day averageMaterial filing
100150200250Aug 25Oct 25Dec 25Feb 26Apr 26Jun 26Aug 26
260 sessions · hover for the filing behind a move
1 week
−0.64%
1 month
−8.29%
3 months
−16.50%
6 months
+53.17%
1 year
+37.06%

The read

written from the numbers on this page
The evidence leans constructive6 supporting, 1 against, 1 worth knowing

Supporting

  • trading 19% above its 200-day average
  • up 37% over twelve months
  • 5 independent kinds of evidence agree today, which is uncommon
  • revenue grew 137% year on year in the quarter ending 2026-06-30
  • net margin has widened from -533.3% to -52.1% across four quarters
  • priced at 4× earnings against an industry median of 44× — 91% below its peers

Against

  • 1 of the scans it matches has historically underperformed the market

Worth knowing

  • the 50-day and 200-day averages disagree, which usually means a turn in progress rather than a trend to lean on
What would change this read: a close below 165, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.

What is working, what is not

read from the filings, with the figure behind every line
Working3

Revenue +210.4% year on year, Rs 13 cr to Rs 40 cr.

+210.4%Rs 13 crRs 40 cr

Net margin moved from -834.6% to -52.1%.

-834.6%-52.1%

Profit rose year on year in all 4 of the last 4 quarters.

4
Needs watching1

Operating cash flow was only Rs -239 cr against Rs 1,581 cr of reported profit, -15% of it.

Rs -239 crRs 1,581 cr-15%
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.

How it has performed

price return over each window, measured against zero
-0.6%1W-8.3%1M-16.5%3M+53.2%6M+37.1%1Y

What the scans say today

8 of 47 matched on 2026-08-21
SPARC matches 8 of the 47 scans today, across 5 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.

Quality of the business

balance sheet as at 2026-03-31
Return on equity
118.1%
trailing profit over shareholders’ funds
Return on capital
83.4%
pre-tax profit over equity plus borrowings
Debt to equity
0.42×
556 cr borrowed against 1,339 cr of equity
Net debt
555 cr
borrowings less cash
Cash conversion
-15%
operating cash flow as a share of profit
Receivable days
2
how long customers take to pay
Return on capital uses profit before tax over equity plus borrowings. The textbook version adds finance costs back; those are not tagged reliably in quarterly filings, so this understates the ratio for a heavily borrowed company rather than flattering it. Balance sheets are filed half-yearly, so these can be up to six months behind the profit figures above.

Valuation against its own history

70 sessions since 2026-05-18
median 5×
now 4×
SPARC trades at trailing earnings, below its median of 5× over this window — 14% less expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.

Recent filings

from the exchange, newest first
08-11
11:55
Other filing
1d-0.85d-3.820d
08-10
14:56
Other filing
1d-2.75d-6.320d
08-10
13:33
Results
1d-2.75d-6.320d
08-10
13:28
Board meeting
1d-2.75d-6.320d
Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093) · AGM / EGM filings were typically +0.00pt vs the market over the next 5 sessions (n=4,362) · Results filings were typically -0.52pt vs the market over the next 5 sessions (n=7,520)

The business

from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
141717131581.9k40-719.0%-951.7%95.0%-52.1%Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q3 FY26Q4 FY26Q1 FY27
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.

Going for it

  • revenue grew 137% against the same quarter a year earlier

Going against it

  • profit dropped 78% year on year
  • net margin narrowed from 95.0% to -52.1%
Quarter-by-quarter numbers, as filed
QuarterRevenueProfit before taxNet profitEPSNet margin
Q1 FY27
2026-06-30 · consolidated
40-21-21-52.1%
Q4 FY26
2026-03-31 · consolidated
1,8531,7611,76154.2795.0%
Q3 FY26
2025-12-31 · consolidated
8-80-80-951.7%
Q3 FY25
2024-12-31 · consolidated
15-79-80-2.45-533.3%
Q2 FY25
2024-09-30 · consolidated
13-107-107-3.31-834.6%
Q1 FY25
2024-06-30 · consolidated
17-96-96-2.96-570.5%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.

Where the price stands

the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-13.1%
Versus 200-day average+19.1%
Below 52-week high-29.1%
Above 52-week low+80.9%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)39.0
Higher closes in last 52 of 5
Six-month return+53.17%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.74%
Volume versus 20-day0.3x
Median daily turnoverRs 16.8 cr

Peers

Healthcare · 67 classified companies
SPARC trades at 4.0× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — cheaper than them, by 91%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
CompanyMarket cap (Rs cr)P/E1 month1 yearTurnover (Rs cr)
SUNPHARMA456,44338.3−2.64%+21.54%363.8
DIVISLAB227,82077.9+17.69%+40.46%315.4
TORNTPHARM165,72780.1−3.33%+36.66%212.0
APOLLOHOSP125,00557.6−1.91%+13.16%257.5
CIPLA115,70034.5+2.81%−8.73%119.7
ZYDUSLIFE111,77625.5+0.56%+12.44%112.7
LUPIN100,67718.1−8.12%+16.52%259.0
MANKIND98,45947.6−6.78%−6.26%81.8
DRREDDY98,08730.8+0.72%−6.30%205.2
LAURUSLABS97,35389.3+14.90%+109.51%286.4
MAXHEALTH97,32466.8−7.77%−13.93%185.4
SPARC6,3834.0−8.29%+37.06%16.8
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet

Recent sessions

what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
SessionScansWhich
2026-08-212Keeping more of every rupee, Earns well on the capital it uses